Naoko Takebe to Poly(ADP-ribose) Polymerase Inhibitors
This is a "connection" page, showing publications Naoko Takebe has written about Poly(ADP-ribose) Polymerase Inhibitors.
Connection Strength
0.285
-
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors. JCO Precis Oncol. 2025 Jul; 9:e2500055.
Score: 0.231
-
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. Oncologist. 2024 Jul 05; 29(7):638-e952.
Score: 0.054